基于PET的TheraP资格标准与接受177Lu-PSMA-617治疗的VISION合格转移性去势抵抗性前列腺癌患者的结局:18F-FDG高摄取不一致发现的重要性
本研究评估了TheraP资格标准与基于VISION标准接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者结局的关联。75例患者中31例(41%)为TheraP不合格,其中24例为不一致病变。TheraP不合格患者PSA50率更低(28% vs 67%),PSA进展风险更高(HR 2.0),总生存期在TheraP不合格组数值上更短但仅边缘显著(10.4个月 vs 未达到;HR 1.9;P=0.054)。不一致病变是不良OS的主要驱动因素。
要点
- 在VISION合格并接受LuPSMA治疗的患者中,41%(31/75)为TheraP不合格。
- TheraP不合格患者PSA50率28% vs TheraP合格67%,PSA进展风险HR 2.0。
- 不一致病变患者死亡风险更高(HR 2.3),且校正后仍为OS的预后因素(HR 3.0)。
核心结论
- 在基于VISION标准接受LuPSMA治疗的患者中,TheraP不合格且存在不一致发现的患者PSA50率、PSA-PFS和OS更差。
- 研究提示TheraP不合格患者OS较短主要由不一致病变的存在驱动。
研究设计与样本
- 连续纳入接受LuPSMA治疗且治疗前接受PSMA PET和18F-FDG PET的患者,共75例。
- 按TheraP标准分为TheraP合格(TheraP-E)与TheraP不合格(TheraP-I),后者再分为低PSMA摄取和不一致病变。
- 采用逻辑回归计算PSA50的比值比,采用Cox回归计算PSA-PFS和OS的风险比,多变量分析校正基线影像和临床参数。
主要发现
- 75例患者中31例(41%)为TheraP-I,其中24例为不一致病变。
- TheraP-I患者PSA50率28% vs TheraP-E患者67%(OR 0.19;95%CI 0.06-0.52;P=0.002)。
- TheraP-I患者PSA进展风险更高(HR 2.0;95%CI 1.2-3.3;P=0.007)。
- TheraP-I组OS数值上短于TheraP-E组,但比较仅边缘显著(10.4个月 vs 未达到;HR 1.9;95%CI 1.0-3.7;P=0.054)。
- TheraP-I中低PSMA摄取患者死亡风险与TheraP-E无显著差异(P=0.9),而不一致病变患者死亡风险更高(HR 2.3;95%CI 1.1-4.6;P=0.02);校正基线影像和临床参数后,不一致病变仍为OS的预后因素(HR 3.0;95%CI 1.3-6.8;P=0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with 177Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION and required 18F-FDG PET to exclude patients with discordant findings. Although the screen-failed patients had shorter overall survival (OS) than those treated with LuPSMA, it remains unclear whether their outcomes might have been modified if they had been exposed to LuPSMA. In this study, we evaluated associations between the TheraP eligibility criteria and subgroups and the treatment outcomes of patients who were deemed suitable and treated on the basis of VISION criteria. Methods: Consecutive patients who were treated with LuPSMA and who underwent pretreatment PSMA and 18F-FDG PET were classified as TheraP-eligible (TheraP-E) and TheraP-ineligible (TheraP-I), the latter of which were subclassified as low PSMA or discordant. Odds ratios for an at least 50% decline in prostate-specific antigen (PSA50) were computed using logistic regression, and hazard ratios (HRs) for PSA progression-free survival (PSA-PFS) and OS were computed using Cox regressions. Multivariable analyses were adjusted for baseline imaging and clinical parameters. Results: Of 75 patients, 31 (41%) were deemed TheraP-I; of those, 24 were subclassified as having discordant disease. TheraP-I patients had a lower PSA50 rate than that of TheraP-E patients (28% vs. 67%; odds ratio, 0.19; 95% CI, 0.06-0.52; P = 0.002) and a higher risk of PSA progression (HR, 2.0; 95% CI, 1.2-3.3; P = 0.007). OS in the TheraP-I group was numerically shorter than in the TheraP-E group, but the comparison was only marginally significant (10.4 mo vs. not reached; HR, 1.9; 95% CI, 1.0-3.7; P = 0.054). TheraP-I patients with low PSMA had no significantly different risk of death (P = 0.9) from that of TheraP-E patients, but those with discordant findings had higher risk of death (HR, 2.3; 95% CI, 1.1-4.6; P = 0.02). Discordant disease remained prognostic for OS after adjusting for baseline imaging and clinical parameters (HR, 3.0; 95% CI, 1.3-6.8; P = 0.01). Conclusion: In VISION-eligible patients who were treated with LuPSMA, TheraP-I patients with discordant findings had lower PSA50, PSA-PFS, and OS. Our study suggests that the shorter OS of TheraP-I patients is mainly driven by the presence of discordant disease.
引用
- Demirci RA, Ghodsi A, Gulati R, et al. PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings. J Nucl Med. 2025. PMID: 39542703. doi:10.2967/jnumed.124.268167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。